Home/ Stocks/ TVGN

Tevogen Bio Holdings Inc. Common Stock

TVGN XNAS

$7.48 +0.00 (+0.00%) ▲ 15-min delayed

Open

$7.50

High

$7.50

Low

$7.00

Volume

8.8K

Market Cap

$31.32M

About Tevogen Bio Holdings Inc. Common Stock

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 18 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$-195,618	$-26,275,432	$-8.08
FY 2025	$-195,618	$-26,275,432	$-8.08
Q3 2025	$-62,340	$-5,726,812	$-0.03
Q2 2025	$-38,033	$-5,503,979	$-0.03

Related Market News

No specific coverage for TVGN yet. Check out our latest market news or earnings calendar.

Get TVGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Tevogen Bio Holdings Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.